GH Research PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GHRS research report →
About the company
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients.
- CEO
- Velichka Valcheva
- IPO
- 2021
- Employees
- 50
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $1.45B
- P/E
- -23.22
- P/S
- 0.00
- P/B
- 4.97
- EV/EBITDA
- -21.58
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -19.83%
- ROIC
- -25.28%
- Revenue
- $0 · 0.00%
- Net Income
- $-48,257,999 · -23.86%
- EPS
- $-0.79 · -5.33%
- Op Income
- $-60,675,999
- FCF YoY
- -3.16%
- 52W High
- $25.94
- 52W Low
- $11.32
- 50D MA
- $20.32
- 200D MA
- $15.81
- Beta
- 1.31
- Avg Volume
- 230.85K
Get TickerSpark's AI analysis on GHRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Moore Duncan | other | 0 |
| Mar 18, 26 | Moore Duncan | other | 4,667 |
| Mar 18, 26 | Cameron Aaron Luke | other | 33,211 |
| Mar 18, 26 | Cameron Aaron Luke | other | 100,000 |
| Mar 18, 26 | Cameron Aaron Luke | other | 25,000 |
| Mar 18, 26 | Hanley Dermot John | other | 0 |
| Mar 18, 26 | Hanley Dermot John | other | 4,667 |
| Mar 18, 26 | Halle Magnus Clemensen | other | 0 |
| Mar 18, 26 | Halle Magnus Clemensen | other | 50,000 |
| Mar 18, 26 | Forer Michael | other | 0 |
Our GHRS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GHRS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.